Best Brachytherapy for uterine cancer Doctors Worldwide — TOP 29

Prof. Merimsky leads the Soft Tissue and Bone Oncology Unit at Sourasky Medical Center, specializing in brachytherapy for uterine cancer.

• Over 41 years of experience of experience in oncology
• Trained in brachytherapy at NY Hospital Medical Center of Queens
• Member of ESMO Sarcoma group faculty
• Published research on tumor immunology

Specialist in oncological gynecology and radiotherapy at Sourasky Medical Center (Ichilov).

• Focused expertise in combining gynecologic oncology with radiotherapy
• Works at a leading medical center in Israel
• Specialized approach to uterine cancer treatment

Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.

Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.

Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.

He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.

Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.

He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).

He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.

Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Dr. Ferentinos leads the Radiation Oncology Department at German Oncology Center, specializing in precise cancer treatments.

• Over 13 years of experience of experience in radiation oncology
• Specializes in interventional radiation oncology techniques
• Holds a doctoral degree from Johann Wolfgang Goethe University
• Currently pursuing a Master's in Healthcare Business Studies

Dr. Mustafa Solak specializes in various cancers, including uterine cases, with training from Hacettepe University Cancer Institute and MD Anderson Cancer Center.

• Expert in breast, ovarian, and gastrointestinal cancers
• Completed fellowship at a top-tier cancer institute
• Trained at MD Anderson – a global leader in oncology
• Over a decade of experience in cancer treatment

Director of oncology hospitalization at Tel Aviv Medical Center – Dr. Stepfansky specializes in brachytherapy for uterine cancer.

• 26 years of experience of clinical experience in oncology
• Internship and training at Tel Aviv Medical Center
• Involved in clinical studies across all trial phases
• Specializes in internal medicine and oncology

Specializes in brachytherapy for uterine cancer – trained at Anderson Cancer Center and coordinates treatment for female reproductive system tumors at Sourasky Medical Center.

• Completed residency in general oncology and radiotherapy at Sheba Hospital
• Fellowship at Anderson Cancer Center, Houston, Texas
• Research focuses on brachytherapy in oncogynecology
• Member of Israel Society of Oncology and Clinical Radiotherapy
• Recognized as best hospital employee in 2007

Expert in brachytherapy with 14 years of experience in oncology – Phd Viola Fox leads a certified cancer center in Solingen.

• Specialized in chemotherapy, immunotherapy, and radiation therapy
• Member of German and American cancer research societies
• Qualified in genetics for tailored cancer treatments
• Publishes research on molecular biology in cancer therapy

Specializes in brachytherapy for uterine cancer at Medical Park Antalya Hospital Complex – experienced in medical oncology with over 20 years of experience of practice.

• Board-certified in medical oncology since 2018
• Works with a multidisciplinary oncology team
• Completes ongoing training in advanced radiation therapy techniques

Specializes in radiotherapy with a focus on brachytherapy for uterine cancer at Nordwest Clinic.

• Radiotherapy specialist with extensive experience
• Works at Nordwest Clinic – a leading medical facility
• Focuses on precise and effective treatment methods

Prof. Dr. Gül Alço is a radiation oncologist with about 27 years of experience. She treats breast, lung, prostate, gastrointestinal, gynecologic, central nervous system, head and neck, soft tissue, and bone cancers with radiotherapy.

Her expertise includes adaptive radiotherapy and radiosurgery. She uses advanced radiation techniques to provide personalized, evidence-based care in a multidisciplinary, patient-centered setting.

Prof. Dr. Abdullah Sakin is a professor of medical oncology. He treats solid tumors, including lung, breast, gastrointestinal, genitourinary, gynecologic, head and neck cancers, and melanoma.

He delivers personalized, evidence-based care. His treatments include chemotherapy, targeted therapy, immunotherapy, hormone therapy, and precision oncology. He has authored more than 200 scientific publications and takes part in international clinical research. This work advances patient-centered cancer care.